Published in

American Society for Microbiology, Journal of Clinical Microbiology, 12(59), 2021

DOI: 10.1128/jcm.01229-21

Links

Tools

Export citation

Search in Google Scholar

Aspergillus test profiles and mortality in critically-ill COVID-19 patients

Journal article published in 2021 by Mehmet Ergün ORCID, Roger J. M. Brüggemann ORCID, Alexandre Alanio ORCID, Sarah Dellière ORCID, Andreas van Arkel, Robbert G. Bentvelsen, Tom Rijpstra, Simone van der Sar-Van der Brugge, Katrien Lagrou, Nico A. F. Janssen, Jochem B. Buil ORCID, Karin van Dijk, Willem J. G. Melchers, Monique H. E. Reijers, Jeroen A. Schouten and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The literature regarding COVID-19-associated pulmonary aspergillosis (CAPA) has shown conflicting observations, including survival of CAPA patients not receiving antifungal therapy and discrepancy between CAPA diagnosis and autopsy findings. To gain insight into the pathophysiology of CAPA, we performed a case-control study in which we compared Aspergillus test profiles in CAPA patients and controls in relation to intensive care unit (ICU) mortality.